Skip to main content

Table 8 Protective efficacy based on mITT by pooled group

From: Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries

Studies pooled Treatment N # of failures Person-years Incidence densitya PE 95 % CI lower limit 95 % CI upper limit
030 and 045 Placebo 187 116 22.91 506.3    
Tafenoquine 200-mg weekly 190 14 42.23 33.2 93.5 88.6 96.2
Mefloquine 250-mg weekly 142 8 28.67 27.9 94.5 88.7 97.3
030, 043 and 045 Placebo 247 170 30.59 555.7    
Tafenoquine 200-mg weekly 245 21 54.44 38.6 93.1 89.1 95.6
  1. CI confidence interval, mITT modified intent-to-treat, N number of subjects, PE protective efficacy
  2. aIncidence density rate is expressed in terms of number of prophylactic failures per 100 person-years